Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease

Experimental and Therapeutic Medicine

Volumn 2, Issue 5, 2011, Pages 783-786

  Osaki, Rie ^a   Imaeda, Hirotsugu ^a   Ban, Hiromitsu ^a   Aomatsu, Tomoki ^a   Bamba, Shigeki ^a   Tsujikawa, Tomoyuki ^a   Sasaki, Masaya ^a   Fujiyama, Yoshihide ^a   Andoh, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

6 thioguanine nucleotide; Azathioprine; Crohn's disease; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; INOSINE TRIPHOSPHATE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; MERCAPTOPURINE; MULTIDRUG RESISTANCE PROTEIN 4; PHOSPHATASE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ACCURACY; ADVERSE OUTCOME; ALLELE; ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; ENTERITIS; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE; MAJOR CLINICAL STUDY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; REMISSION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

EID: 79960263432     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.287     Document Type: Article

References (30)

1. Adler DJ and Korelitz BI: The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85: 717-722, 1990.
2. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R and Prantera C: Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 6: CD000545, 2000.
3. Hibi T and Ogata H: Novel pathophysiological concepts of inflammatory bowel disease. J Gastroenterol 41: 10-16, 2006.
4. Gearry RB, Barclay ML, Burt MJ, Collett JA and Chapman BA: Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 13: 563-567, 2004.
5. Van Dieren JM, Hansen BE, Kuipers EJ, Nieuwenhuis EE and Van der Woude CJ: Meta-analysis: inosine triphosphate pyrophosphatase polymorphisms and thiopurine toxicity in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 26: 643-652, 2007.
6. Gisbert JP and Gomollon F: Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 103: 1783-1800, 2008.
7. Takatsu N, Matsui T, Murakami Y, et al: Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 24: 1258-1264, 2009.
8. Lees CW, Maan AK, Hansoti B, Satsangi J and Arnott ID: Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease. Aliment Pharmacol Ther 27: 220-227, 2008.
9. Winter JW, Gaffney D, Shapiro D, et al: Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease. Aliment Pharmacol Ther 25: 1069-1077, 2007.
10. Lichtenstein GR, Sbreu MT, Cohen R and Tremaine W: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Rev Gastroenterol Mex 71: 351-401, 2006 (In Spanish).
11. Hibi T, Naganuma M, Kitahora T, Kinjyo F and Shimoyama T: Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 38: 740-746, 2003.
12. Derijks LJ, Gilissen LP, Engels LG, et al: Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease. Ther Drug Monit 28: 45-50, 2006.
13. Haglund S, Taipalensuu J, Peterson C and Almer S: IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations. Br J Clin Pharmacol 65: 69-77, 2007.
14. Ban H, Andoh A, Tanaka A, et al: Analysis of thiopurine S-methyltransferase genotypes in Japanese patients with inflammatory bowel disease. Intern Med 47: 1645-1648, 2008.
15. Hiratsuka M, Inoue T, Omori F, Agatsuma Y and Mizugaki M: Genetic analysis of thiopurine methyltransferase polymorphism in a Japanese population. Mutat Res 448: 91-95, 2000.
16. Uchiyama K, Nakamura M, Kubota T, Yamane T, Fujise K and Tajiri H: Thiopurine S-methyltransferase and inosine triphosphate pyrophosphohydrolase genes in Japanese patients with inflammatory bowel disease in whom adverse drug reactions were induced by azathioprine/6-mercaptopurine treatment. J Gastroenterol 44: 197-203, 2009.
17. Kurzawski M, Dziewanowski K, Lener A and Drozdzik M: TPMT but not ITPA gene polymorphism influences the risk of azathioprine intolerance in renal transplant recipients. Eur J Clin Pharmacol 65: 533-540, 2009.
18. Allorge D, Hamdan R, Broly F, Libersa C and Colombel JF: ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54: 565, 2005.
19. Zelinkova Z, Derijks LJ, Stokkers PC, et al: Inosine triphosphate pyrophosphatase and thiopurine s-methyltransferase genotypes relationship to azathioprine-induced myelosuppression. Clin Gastroenterol Hepatol 4: 44-49, 2006.
20. Wielinga PR, Reid G, Challa EE, et al: Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells. Mol Pharmacol 62: 1321-1331, 2002.
21. Krishnamurthy P, Schwab M, Takenaka K, et al: Transporter-mediated protection against thiopurine-induced hematopoietic toxicity. Cancer Res 68: 4983-4989, 2008.
22. Peng XX, Shi Z, Damaraju VL, et al: Up-regulation of MRP4 and down-regulation of influx transporters in human leukemic cells with acquired resistance to 6-mercaptopurine. Leuk Res 32: 799-809, 2008.
23. Borst P, Evers R, Kool M and Wijnholds J: A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92: 1295-1302, 2000.
24. Ban H, Andoh A, Imaeda H, et al: The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J Gastroenterol 45: 1014-1021, 2010.
25. Yates CR, Krynetski EY, Loennechen T, et al: Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126: 608-614, 1997.
26. Marinaki AM, Ansari A, Duley JA, et al: Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 14: 181-187, 2004.
27. Hui L, DelMonte T and Ranade K: Genotyping using the TaqMan assay. In: Current Protocols Human Genetics. Haines JL (ed). John Wiley, New York, 2008.
28. Mitani Y, Lezhava A, Sakurai A, et al: Rapid and cost-effective SNP detection method: application of SmartAmp2 to pharmacogenomics research. Pharmacogenomics 10: 1187-1197, 2009.
29. Morita A, Nakayama T, Doba N, Hinohara S, Mizutani T and Soma M: Genotyping of triallelic SNPs using TaqMan PCR. Mol Cell Probes 21: 171-176, 2007.
30. Livak KJ: Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 14: 143-149, 1999.